Against a backdrop of repeated industry challenges in court, the Centers for Medicare and Medicaid Services (CMS) is locking ...

AstraZeneca may not need a major acquisition to sustain growth beyond 2030—but the British pharma is reportedly not stopping ...

The case is the latest in a series of challenges that Lilly and Novo have brought against companies providing compounded ...

ViiV Healthcare has tapped a new mind for its “PrEP Wisdom” campaign, with Tony Award-winning actor and fashion icon Jeremy ...

Amid surging sales of Rezdiffra, Madrigal Pharmaceuticals is facing a whistleblower lawsuit alleging that senior leadership ...

Knudsen’s departure will mark the end of a 27-year run at Novo, with Doustdar telling analysts Wednesday that the outgoing ...

Alnylam Pharmaceuticals is seeking a new chief commercial officer as the biopharma announced that its six-year CCO veteran ...

ANI Pharmaceuticals is forking over more than half a billion dollars to broaden its rare disease business. | ANI ...

Merck & Co. is chasing the finish line with its eye on one prize: a world without cancer. | In “From Our Pipeline to the ...

Would you know the difference between a normal cold and one that has turned into something more serious? | Would you know the ...

Facing looming patent cliffs, AstraZeneca has launched a restructuring initiative aimed at generating $1.5 billion in annual ...

Bayer’s pharmaceutical business may finally be entering a long-awaited growth cycle, but CEO Bill Anderson still can’t quite ...